TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) announces that, with the aim of becoming a company in which each individual can truly derive a sense of the joy and satisfaction of working and envision a bright future and new possibilities, it has established a new company, TANAKA PRECIOUS […]

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW HAVEN, Conn., Jan. 05, 2026 (GLOBE NEWSWIRE) — SynuSight Biotech (“SynuSight”), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics

(NasdaqGM:WW), NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk's newly FDA approved oral formulation of Wegovy(R) through its integrated GLP-1 platform. The addition of a once-daily Wegovy pill expands access to GLP-1 treatment and reinforces

(NasdaqGM:LFMD),(NasdaqGM:LFMDP), NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk's Wegovy(R) (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — Kriya Therapeutics, Inc. (“Kriya”), a clinical-stage biopharmaceutical company developing life-changing gene therapies for conditions affecting millions of people around the world, today announced the appointment of Sachiyo Minegishi as Chief Financial Officer. Ms. Minegishi will oversee execution of Kriya's corporate strategy, scaling of financial operations

— Proven financial and strategic leader with over two decades of experience driving organizational growth, operational excellence, and longâ€'term value creation — WALTHAM, Mass. and SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc., an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy(R) Pill Adds first and only FDAâ€'approved oral GLPâ€'1 to its virtual weight management offering, expanding access to affordable, branded treatment options GlobeNewswire January 05, 2026 NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of

SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson's Disease GlobeNewswire January 05, 2026 SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and

Kriya Appoints Sachiyo Minegishi as Chief Financial Officer Seasoned biotech executive with a track record of guiding corporate development, financial strategy and commercialization for public and private biopharma companies GlobeNewswire January 05, 2026 RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — Kriya Therapeutics, Inc. (“Kriya”), a clinical-stage biopharmaceutical company developing life-changing gene therapies

Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy(R) Pill Advancing a New Standard for Long-Term Weight Health A NovoCare(R) Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone GlobeNewswire January 05, 2026 NEW YORK, Jan. 05, 2026